United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $476.34, for a total value of $3,953,622.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's

Get a deeper insight into the potential performance of United Therapeutics (UTHR) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Shell Asset Management Co. cut its holdings in United Therapeutics Corporation (NASDAQ: UTHR) by 83.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 394 shares of the biotechnology company's stock after selling 1,917 shares during the period. Shell Asset Management

Guru Stock PicksLouis Moore Bacon has made the following transactions:Reduce in XLF by 69.62%Sold out in CEGAdd in CLS by 386.7%New position in CLJoel Greenblat

United Therapeutics (NASDAQ: UTHR - Get Free Report) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $6.73 per share and revenue of $814.8010 million for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025

Envestnet Asset Management Inc. cut its position in United Therapeutics Corporation (NASDAQ: UTHR) by 20.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,820 shares of the biotechnology company's stock after selling 15,252 shares during the period.

Exploring the Latest 13F Filing and Investment Shifts Renaissance Technologies (Trades, Portfolio) recently submitted its 13F filing for the fourth quarter of

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The transaction was disclosed in a legal filing with the SEC, which is

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, February 25, 2026, at 9:00 a.m. Eastern Time. The webcast will b.

Candriam S.C.A. grew its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 48.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 123,387 shares of the biotechnology company's stock after purchasing an additional 40,176 shares during the quarter. Candriam S.C.A.